TNF-α inhibitor–induced psoriasis: A decade of experience at the Cleveland Clinic

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

Cornelia Tillack, Laura Maximiliane Ehmann, Matthias Friedrich et al. · Gut · 2013 · 297 citations

Medicine, Dermatology, Immunology +17

Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?

Dominique Baeten · Annals of the Rheumatic Diseases · 2003 · 187 citations · Full text

Medicine, Immunology, Pharmacotherapy +9

Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Stephen Jarrett, Gaye Cunnane, Philip G. Conaghan et al. · PubMed · 2003 · 173 citations

Medicine, Immunology, Internal Medicine +17

Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy

Jean‐François Rahier, S. Buche, Laurent Peyrin‐Biroulet et al. · Clinical Gastroenterology and Hepatology · 2010 · 165 citations · Full text

Medicine, Dermatology, Immunology +14

Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010

Eugenia Shmidt, David A. Wetter, Sara B. Ferguson et al. · Journal of the American Academy of Dermatology · 2011 · 134 citations

Medicine, Dermatology, Immunology +16